•
IN
INKT
MiNK Therapeutics, Inc. Common Stock
polygonBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
57.64M
Volume
1.37K
52W High
$76.00
52W Low
$4.56
Open
$12.16
Prev Close
$12.28
Day Range
12.16 - 12.30
About MiNK Therapeutics, Inc. Common Stock
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
Latest News
MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
GlobeNewswire Inc.•Nov 7
MiNK Therapeutics Cuts Q2 Cash Use 31%
The Motley Fool•Aug 14
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
GlobeNewswire Inc.•Jun 10
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
GlobeNewswire Inc.•Feb 12
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
GlobeNewswire Inc.•Jan 23
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
GlobeNewswire Inc.•Jun 5
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
GlobeNewswire Inc.•May 22
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
GlobeNewswire Inc.•May 13